Global Colony Stimulating Factors Market, By Type (Macrophage–Colony-Stimulating Factor (M-CSF), Multiple-Colony-Stimulating Factor, or Interleukin 3 (IL-3), Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF), Granulocyte–Colony-Stimulating Factor (G-CSF)), Drug (Pegfilgrastim, Tbo-filgrastim, Sargramostim, Filgrastim), Application (Aplastic Anemia, Bone Marrow Transplantation, Neutropenia, Neutropenia Associated with Chemotherapy, Neutropenia Associated with Radiation, Peripheral Progenitor Cell Transplantation), Dosage (Tablets, Capsule, Injection, Others), Route of Administration (Intravenous, Subcutaneous, Oral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Colony stimulating factors (CSFs) are hormone-like proteins that promote the creation of immune cells that fight infections. CSFs are produced by a variety of cells in our bodies and can travel throughout the body, binding to cells with specialized CSF receptors. CSFs are used as drugs to promote the formation of white blood cells because they can stimulate the synthesis of immune cells. For those whose immune systems have been decimated by chemotherapy or certain immunodeficiency illnesses, this could be a life-saving treatment. CSFs are also significant drugs utilized in the transplantation of blood stem cells.
Data Bridge Market Research analyses that the colony stimulating factors market was valued at USD 6.98 billion in 2021 and is expected to reach USD 15.74 billion by 2029, registering a CAGR of 10.7% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Type (Macrophage–Colony-Stimulating Factor (M-CSF), Multiple-Colony-Stimulating Factor, or Interleukin 3 (IL-3), Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF), Granulocyte–Colony-Stimulating Factor (G-CSF)), Drug (Pegfilgrastim, Tbo-filgrastim, Sargramostim, Filgrastim), Application (Aplastic Anemia, Bone Marrow Transplantation, Neutropenia, Neutropenia Associated with Chemotherapy, Neutropenia Associated with Radiation, Peripheral Progenitor Cell Transplantation), Dosage (Tablets, Capsule, Injection, Others), Route of Administration (Intravenous, Subcutaneous, Oral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Intas Pharmaceuticals Ltd. (India), Sanofi (France), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Biocon (India), Dr. Reddy’s Laboratories Ltd. (India), Amgen Inc. (US), Merck KGaA (Germany), Takeda Pharmaceutical Company Limited (Japan), Thermo Fisher Scientific Inc. (US), STADA Arzneimittel AG (Germany), Emcure Pharmaceuticals Limited. (India), CELLTRION INC. (South Korea), BIOCAD (Russia), Coherus BioSciences (US), Johnson & Johnson Private Limited (US), Eli Lilly and Company (US), Abbott (US)
In response to infection, colony stimulating factors are glycoproteins that encourage the development of white blood cells (mostly granulocytes such as neutrophils). Exogenous colony stimulating substances encourage stem cells in the bone marrow to create more of a certain type of white blood cell. The new white blood cells enter the bloodstream and begin fighting the illness. Patients who are receiving cancer treatment that induces low white blood cell counts (neutropenia) and puts them at risk of infection are given colony stimulating agents. Patients that get colony stimulating substances spend less time neutropenic.
Colony Stimulating Factors Market Dynamics
- Increasing prevalence of cancer
The rising prevalence of cancer is anticipated to influence the growth of the colony stimulating factors in the market. Cancer is the second leading cause of death, accounting for around one in every six deaths globally. According to the International Agency for Research on Cancer (IARC), population growth and ageing are expected to increase the worldwide burden of cancer to 27.5 million active cancer occurrences and 16.3 million cancer deaths by 2040. Low- as well as middle-income nations account for over 70% of cancer mortality. G-CSF is a type of growth factor that helps the bone marrow create white blood cells, reducing the risk of infection and sepsis. Granulocyte–Colony-Stimulating Factor (G-CSF) aids cancer patients recover quicker and decreases the risk of death from neutropenia. It may also help to prevent infection during cancer therapy.
- Rising demand for prophylaxis granulocyte colony-stimulating factor (G-CSF)
The increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is expected to flourish the market’s growth rate during the forecast period of 2022-2029. G-CSF prophylaxis reduces the risk of febrile neutropenia (FN), allowing patients to continue receiving myelosuppressive treatment. Over the next ten years, current G-CSF prophylaxis offers significant benefits, including a reduction in febrile neutropenia instances by 3.3 million and a reduction in chemotherapy dosage intensity by less than 85 percent.
Furthermore, rising initiatives by public and private organizations to spread awareness availability of various methods of cancer treatment will expand the colony stimulating factors market. Additionally, rising level of governmental funding towards healthcare and increasing geriatric population will result in the expansion of colony stimulating factors market. Along with this, rising use of bone and blood marrow transplantation to treat blood diseases and favourable reimbursement policies will enhance the market's growth rate.
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research activities to develop therapies for management of maliganancies and their complications. This will provide beneficial opportunities for the colony stimulating factors market growth.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the colony stimulating factors market growth during the forecast period.
- High cost associated with the colony stimulating factors agents
The increase in immediate medical costs in breast cancer patients taking primary preventive (PP) G-CSF can be attributed to improved chemotherapy administration. According to a study published in the American Journal of Managed Care, PPG-CSF administration in the first chemotherapy class was linked to a 57 percent rise in overall Medicare costs throughout the research period, despite a decrease in medical costs for neutropenia. Chemotherapy prices have increased by 42%. PPG-CSF costs higher with each shot. As a result, the colony stimulating factors market is projected to be hampered by its high cost.
On the other hand, the dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the colony stimulating factors market. Additionally, side effects of colony stimulating factors and stringent government regulations for approval of any new treatment options will act as market restrain and further impede market growth rate during the forecast period of 2022-2029.
This colony stimulating factors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the colony stimulating factors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Colony stimulating factors market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Colony Stimulating Factors Market
Due to lockdowns, travel bans, and business shutdowns, the COVID-19 pandemic had impacted economies and businesses in a number of countries. The closure of numerous plants and factories severely influenced global supply chains, affecting manufacturing, delivery schedules, and product sales. There has been a significant shift in cancer treatment as a result of the limitations and lockdowns enforced, as patients were unable to travel out for their treatments, which was affecting the market growth of colony stimulating factors.
However, COVID-19 disease requires immediate treatment. The myelopoietic development factor and pro-inflammatory cytokine GM-CSF plays a critical role in lung inflammation, immunological illness, and alveolar macrophage homeostasis. In COVID-19 clinical trials, both inhibition and delivery of GM-CSF are being investigated. As a result, the demand of colony stimulating factors market is increased.
Global Colony Stimulating Factors Market Scope
The colony stimulating factors market is segmented on the basis of type, drug, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Macrophage–Colony-Stimulating Factor (M-CSF)
- Multiple-Colony-Stimulating Factor, or Interleukin 3 (IL-3)
- Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF)
- Granulocyte–Colony-Stimulating Factor (G-CSF)
- Aplastic Anemia
- Bone Marrow Transplantation
- Neutropenia Associated with Chemotherapy
- Neutropenia Associated with Radiation
- Peripheral Progenitor Cell Transplantation
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Colony Stimulating Factors Market Regional Analysis/Insights
The colony stimulating factors market is analysed and market size insights and trends are provided by country, type, drug, application, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the colony stimulating factors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the colony stimulating factors market because of the rising prevalence of cancer in this region. Additionally, the growing presence of major key players and well-established healthcare infrastructure will further propel the market’s growth rate.
Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to rising healthcare expenditure and improvements in healthcare infrastructure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Colony Stimulating Factors Market Share Analysis
The colony stimulating factors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to colony stimulating factors market.
Some of the major players operating in the colony stimulating factors market are:
- Intas Pharmaceuticals Ltd. (India)
- Sanofi (France)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Biocon (India)
- Dr. Reddy’s Laboratories Ltd. (India)
- Amgen Inc. (US)
- Merck KGaA (Germany)
- Takeda Pharmaceutical Company Limited (Japan)
- Thermo Fisher Scientific Inc. (US)
- STADA Arzneimittel AG (Germany)
- Emcure Pharmaceuticals Limited. (India)
- CELLTRION INC. (South Korea)
- BIOCAD (Russia)
- Coherus BioSciences (US)
- Johnson & Johnson Private Limited (US)
- Eli Lilly and Company (US)
- Abbott (US)
Research Methodology: Global Colony Stimulating Factors Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.